Your session is about to expire
← Back to Search
Dialectical Behavior Therapy for Psychosocial Functioning in Veterans
Study Summary
This trial will look into the effectiveness of DBT-J, a program for veterans with criminal justice involvement, to reduce risk of criminal behavior and increase psychosocial functioning.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am a veteran and I am 18 years old or older.
- Group 1: Dialectical Behavior Therapy for Justice-Involved Veterans
- Group 2: Supportive Group Psychotherapy
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any remaining openings for patients to join this trial?
"As per the information accessible on clinicaltrials.gov, this trial is not recruiting patients at present; although first posted in January 2024 and last modified in July 2023, there are 12 other studies that remain actively looking for participants."
What is the ultimate goal of this experimentation?
"This six-month clinical trial intends to assess the Psychosocial Functioning of participants. Secondary evaluations will include a self-reported Measure of Criminogenic Thinking Styles, Patient Health Questionnaire-9, and Alcohol Use Disorders Identification Test."
To what extent does Dialectical Behavior Therapy (DBT) protect Justice-Involved Veterans from potential harm?
"Based on the evidence from past trials, our team at Power estimated that Dialectical Behavior Therapy for Justice-Involved Veterans is safe enough to receive a 3 rating. This score was assigned due to Phase 3 trial results demonstrating both efficacy and safety."
Share this study with friends
Copy Link
Messenger